ENVB

Enveric Biosciences Inc. (ENVB) | Rumor.io

Enveric Biosciences

ENVB

Attention (50-day avg)0%

Attention rank (50-day avg)#3,655

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization6.6M

Earnings per share-12.2

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8.8M

Social

What share of all stock conversation is about ENVB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 4

ENVB may be nearing a bottom, with potential for a quick price increase.
Breaking above $2.10 could give ENVB a boost, while a move past $2.35 could lead to prices over $3.
The current price gap between $4 and the current price is a potential area of focus for ENVB.

Generated by AI

Sentiment

Of the messages about ENVB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	73.41% -8.75
Bearish	—	—	0% 0	26.59% +8.75

Bullish· Apr 28

$ENVB has the potential for a significant price increase, with one post suggesting a move to $6+ and another noting a 11.1% gain from $5.10 to $5.67.
Enveric Biosciences, Inc. is making progress towards IND movement, with a post mentioning that the company expects IND to move forward in Q2 of 2026, which is currently underway.
The company has shown impressive performance, with one post noting a 10.0% gain from $5.10 to $5.61, and another post highlighting a "big W" on ENVB by the QB.

Bearish· Apr 30

ENVB has experienced a significant drop in price, with some investors feeling it was a "dip" to be taken advantage of.
The company's pipeline progress and clinical program expenses may have been underestimated by some investors, leading to a decline in stock value.
ENVB's stock price has been subject to manipulation, with some investors detecting unusual chart patterns and bearish trends.

Generated by AI

Topics

Of the messages about ENVB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	23.68%
Technical Analysis	—	—	16.67%	32.24%
Controversies	—	—	33.33%	0.74%
Analysts	—	—	0%	21.71%
Earnings	—	—	0%	0.08%
Macro	—	—	0%	21.55%

Announcements· Apr 24

Enveric Biosciences, Inc. (ENVB) is developing neuroplastogenic small-molecule therapies targeting depression, anxiety, and addiction disorders.
The company has secured a $13.9M private placement, strengthening its balance sheet and positioning it for key developments in neuroplastogenic therapeutics.
ENVB has seen significant price surges due to various catalysts, including a strategic alliance, a dividend increase, and its participation in the Needham Psychedelics Forum.

Technical Analysis· Apr 24

$ENVB has broken past resistance at $4.44, with a next target at $6.93.
The stock's price surge is attributed to a catalyst in the psychedelics forum, with options flow indicating bullishness.
A high-risk setup with a volatile catalyst is in place, with caution advised and a potential pullback being monitored.

Generated by AI

Community

Of the messages about ENVB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	76.92%	31.08%
Newcomers	—	—	23.08%	68.92%

Regulars· Apr 20

$ENVB is trying to base around $4.20, but it still needs to reclaim and hold $4.50 before momentum can really come back into play.
The stock is attempting to close above its VWAP, and a falling wedge pattern has been identified.
The company's stock has potential for a significant run, with some analysts predicting a 30X increase, and a market cap of over $1 billion.

Newcomers· Apr 27

The newcomers are focused on the recent surge in $ENVB, with some predicting it will continue while others are concerned it may be the peak.
The volume of $ENVB is seen as a key indicator of the momentum's continuation, with some expecting the rally to stretch longer than others.
Some users have set specific price targets for $ENVB, ranging from $5.50 to $6.11, while others have identified potential support and resistance levels.

Generated by AI

CAMBRIDGE, Mass., September 15, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering novel compounds within its EVM401 Series of drug candidates. The EVM401 Series comprises proprietary, non-hal

14d agoYahoo! Finance Canada

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

CAMBRIDGE, Mass., September 01, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced that Joseph Tucker, Ph.D., CEO of Enveric will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investment Conference, which is being held September 14-16, 2026, in New York City.

28d agoYahoo! Finance Canada

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

CAMBRIDGE, Mass., August 14, 2026--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a comprehensive business update.

1mo agoYahoo Finance

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Ca

Enveric Biosciences reports new preclinical data supporting the non-hallucinogenic profile of its lead psychiatric drug candidate, EB-003.

1mo agoBenzinga

Enveric reports preclinical data on EB-003 drug candidate

1mo agoInvesting.com

Also Discussed

Investors talking about ENVB also mention

#	Name	Attention
1	DNA X, Inc.SONM	0%+0
2	Sentage Holdings Inc.SNTG	0%0
3	Alset Inc.AEI	0%0
4	Hepion Pharmaceuticals, Inc.HEPA	0%0
5	NanoVibronix, Inc.NAOV	0%0
6	Farmmi, Inc. Class A Ordinary SharesFAMI	0%0
7	CNDA - Concord Acquisition Corp II	——
8	Aprea Therapeutics, Inc.APRE	0%0
9	ImageneBio, Inc.IKNA	0%0
10	Kaixin HoldingsKXIN	0%0

Enveric Biosciences Inc.

Healthcare
Biotechnology

Enveric Biosciences Inc. is a biotechnology company focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders. The company’s current pipeline centers on novel compounds designed to promote neuroplasticity while avoiding hallucinogenic effects, with a particular emphasis on depression, anxiety, and addiction-related conditions. Its lead program, EB-003, is being developed as a next-generation therapeutic candidate, and the broader research platform includes proprietary chemical libraries and additional preclinical assets aimed at mental health indications. Enveric Biosciences works at the intersection of neuroscience, medicinal chemistry, and drug discovery, positioning itself within the evolving field of psychedelic-inspired and neuropsychiatric medicine. The company is headquartered in Cambridge, Massachusetts.

Website

Location

4851 Tamiami Trail N

Naples, FL, 34103

United States

Social

What share of all stock conversation is about ENVB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 4

ENVB may be nearing a bottom, with potential for a quick price increase.
Breaking above $2.10 could give ENVB a boost, while a move past $2.35 could lead to prices over $3.
The current price gap between $4 and the current price is a potential area of focus for ENVB.

Generated by AI

Sentiment

Of the messages about ENVB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	73.41% -8.75
Bearish	—	—	0% 0	26.59% +8.75

Bullish· Apr 28

$ENVB has the potential for a significant price increase, with one post suggesting a move to $6+ and another noting a 11.1% gain from $5.10 to $5.67.
Enveric Biosciences, Inc. is making progress towards IND movement, with a post mentioning that the company expects IND to move forward in Q2 of 2026, which is currently underway.
The company has shown impressive performance, with one post noting a 10.0% gain from $5.10 to $5.61, and another post highlighting a "big W" on ENVB by the QB.

Bearish· Apr 30

ENVB has experienced a significant drop in price, with some investors feeling it was a "dip" to be taken advantage of.
The company's pipeline progress and clinical program expenses may have been underestimated by some investors, leading to a decline in stock value.
ENVB's stock price has been subject to manipulation, with some investors detecting unusual chart patterns and bearish trends.

Generated by AI

Topics

Of the messages about ENVB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	50%	23.68%
Technical Analysis	—	—	16.67%	32.24%
Controversies	—	—	33.33%	0.74%
Analysts	—	—	0%	21.71%
Earnings	—	—	0%	0.08%
Macro	—	—	0%	21.55%

Announcements· Apr 24

Enveric Biosciences, Inc. (ENVB) is developing neuroplastogenic small-molecule therapies targeting depression, anxiety, and addiction disorders.
The company has secured a $13.9M private placement, strengthening its balance sheet and positioning it for key developments in neuroplastogenic therapeutics.
ENVB has seen significant price surges due to various catalysts, including a strategic alliance, a dividend increase, and its participation in the Needham Psychedelics Forum.

Technical Analysis· Apr 24

$ENVB has broken past resistance at $4.44, with a next target at $6.93.
The stock's price surge is attributed to a catalyst in the psychedelics forum, with options flow indicating bullishness.
A high-risk setup with a volatile catalyst is in place, with caution advised and a potential pullback being monitored.

Generated by AI

Community

Of the messages about ENVB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	76.92%	31.08%
Newcomers	—	—	23.08%	68.92%

Regulars· Apr 20

$ENVB is trying to base around $4.20, but it still needs to reclaim and hold $4.50 before momentum can really come back into play.
The stock is attempting to close above its VWAP, and a falling wedge pattern has been identified.
The company's stock has potential for a significant run, with some analysts predicting a 30X increase, and a market cap of over $1 billion.

Newcomers· Apr 27

The newcomers are focused on the recent surge in $ENVB, with some predicting it will continue while others are concerned it may be the peak.
The volume of $ENVB is seen as a key indicator of the momentum's continuation, with some expecting the rally to stretch longer than others.
Some users have set specific price targets for $ENVB, ranging from $5.50 to $6.11, while others have identified potential support and resistance levels.

Generated by AI

Enveric Biosciences

Social

Jun 4

Bullish· Apr 28

Bearish· Apr 30

Announcements· Apr 24

Technical Analysis· Apr 24

Regulars· Apr 20

Newcomers· Apr 27

Enveric receives U.S. patent allowance for psychiatric compounds

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Ca

Enveric reports preclinical data on EB-003 drug candidate

Also Discussed

Enveric Biosciences Inc.

Company Information

Location

Enveric receives U.S. patent allowance for psychiatric compounds

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

Enveric Biosciences Says New Preclinical Data Confirms Non-Hallucinogenic Profile For Lead Psychiatric Ca

Enveric reports preclinical data on EB-003 drug candidate

Also Discussed

Social

Jun 4

Bullish· Apr 28

Bearish· Apr 30

Announcements· Apr 24

Technical Analysis· Apr 24

Regulars· Apr 20

Newcomers· Apr 27